They further investigated the molecular mechanism of PRMT3 in regulating gemcitabine resistance in pancreatic cancer, finding that PRMT3 enhances chemotherapy resistance by methylating heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) to increase the expression of ATP‐binding cassette transporter G2 (ABCG2) [69]. Here, HNRNPA1 is linked to pancreatic neoplasm.